- Home
- BIIB vs IBKR Comparison
BIIB vs IBKR Comparison
Compare BIIB & IBKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- IBKR
- Stock Information
- Founded
- BIIB 1978
- IBKR 1977
- Country
- BIIB United States
- IBKR United States
- Employees
- BIIB N/A
- IBKR N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- IBKR Investment Bankers/Brokers/Service
- Sector
- BIIB Health Care
- IBKR Finance
- Exchange
- BIIB Nasdaq
- IBKR Nasdaq
- Market Cap
- BIIB 19.9B
- IBKR 16.6B
- IPO Year
- BIIB 1991
- IBKR 2007
- Fundamental
- Price
- BIIB $125.59
- IBKR $209.15
- Analyst Decision
- BIIB Buy
- IBKR Strong Buy
- Analyst Count
- BIIB 27
- IBKR 8
- Target Price
- BIIB $201.26
- IBKR $213.50
- AVG Volume (30 Days)
- BIIB 1.6M
- IBKR 1.3M
- Earning Date
- BIIB 05-01-2025
- IBKR 07-15-2025
- Dividend Yield
- BIIB N/A
- IBKR 0.61%
- EPS Growth
- BIIB 26.39
- IBKR 23.83
- EPS
- BIIB 10.12
- IBKR 7.26
- Revenue
- BIIB $9,816,400,000.00
- IBKR $5,402,000,000.00
- Revenue This Year
- BIIB N/A
- IBKR $7.25
- Revenue Next Year
- BIIB N/A
- IBKR $5.02
- P/E Ratio
- BIIB $12.43
- IBKR $28.80
- Revenue Growth
- BIIB 1.59
- IBKR 18.21
- 52 Week Low
- BIIB $110.04
- IBKR $103.69
- 52 Week High
- BIIB $238.00
- IBKR $236.53
- Technical
- Relative Strength Index (RSI)
- BIIB 55.21
- IBKR 74.60
- Support Level
- BIIB $119.18
- IBKR $201.45
- Resistance Level
- BIIB $124.82
- IBKR $182.46
- Average True Range (ATR)
- BIIB 3.81
- IBKR 4.71
- MACD
- BIIB 1.21
- IBKR 3.92
- Stochastic Oscillator
- BIIB 98.29
- IBKR 97.08
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About IBKR Interactive Brokers Group Inc.
Interactive Brokers is an online brokerage that generates trading commissions (around 31% of net revenue) from facilitating trading in a wide range of products, including equity, options, futures, foreign exchange, bonds, mutual funds, and ETFs. Interactive Brokers also generates net interest income (about 64% of net revenue) from idle client cash and earns fees (about 6% of net revenue) from ancillary services. Principal trading and other miscellaneous activities are small (about 5% of net revenue). The firm derives about 70% of its net revenue from the U.S. and 30% from international markets.